Radioactive Nanoceramics

Synthesis, Radiolabelling and In Vitro Imaging of Multifunctional Nanoceramics

Marina Lledos,[a] Vincenzo Mirabello,[a] Sophia Sarpaki,[a] Haobo Ge,[a] Hubert J. Smugowski,[a] Laurence Carroll,[b] Eric O. Aboagye,[b] Franklin I. Aigbirhio,[c] Stanley W. Botchway,[d] Jonathan R. Dilworth,[e] David G. Calatayud,[a, f] Pawel K. Plucinski,[g] Gareth J. Price,*[a] and Sofia I. Pascu[e][a]

Abstract: Molecular imaging has become a powerful technique in preclinical and clinical research aiming towards the diagnosis of many diseases. In this work, we address the synthetic challenges in achieving lab-scale, batch-to-batch reproducible copper-64- and gallium-68-radiolabelled metal nanoparticles (MNPs) for cellular imaging purposes. Composite NPs incorporating magnetic iron oxide cores with luminescent quantum dots were simultaneously encapsulated within a thin silica shell, yielding water-dispersible, biocompatible and luminescent NPs. Scalable surface modification protocols to attach the radioisotopes ⁶⁴Cu (t_{1/2} = 12.7 h) and ⁶⁸Ga (t_{1/2} = 68 min) in high yields are reported, and are compatible with the time frame of radiolabelling. Confocal and fluorescence lifetime imaging studies confirm the uptake of the encapsulated imaging agents and their cytoplasmic localisation in prostate cancer (PC-3) cells. Cellular viability assays show that the biocompatibility of the system is improved when the fluorophores are encapsulated within a silica shell. The functional and biocompatible SiO₂ matrix represents an ideal platform for the incorporation of ⁶⁴Cu and ⁶⁸Ga radioisotopes with high radiolabelling incorporation.

Introduction

The self-assembly and subsequent surface functionalization of mesoporous silica nanoparticles enable the formation of new materials with highly controllable properties for theranostic nanomedicine.[1,2] Molecular imaging plays a key role in personalized and targeted medicine.[3] Each type of in-vivo imaging technique has its own advantages and limitations such as spatial and/or temporal resolution, sensitivity, signal-to-noise ratio SNR, penetration depth in tissue, quantitative accuracy[4] and differentiating postsurgical residual disease and postschemothrapy/postradiation lesions.[5] It has been acknowledged that there is no single modality, available amongst current molecular imaging techniques, capable to acquire alone all of the essential information across length scales of molecules to tissues and organs. Positron emission tomography (PET) is very sensitive and highly quantitative but has a poor spatial resolution. Magnetic resonance imaging (MRI) has superior resolution compared to PET as well as good soft tissue contrast, but low sensitivity. Optical fluorescence imaging cannot accurately quantify in-vivo fluorescence signals in large (more than 10 mm) living subjects. Thus, a combination of techniques ('multimodal imaging') is an essential tool in imaging at the research stage and in translational studies to a clinical setting.[6,7,8,9] Simultaneous PET-MR imaging is one example,[10] which shows promise for the next generation of dual-modality medical imaging.[11] This requires reliable and batch-to-batch reproducible synthetic methods for new classes of imaging probes.[12] Currently, the most studied dual-modal imaging
agent is based on a PET isotope combined with gadolinium for MRI, but longer-term concerns include the deposition of Gd from linear chelators. Insoluble deposits of gadolinium phosphate have been found in many organs such as skin, liver, lungs, ileum, kidney, skeletal muscles and brain. Recently developed dual-mode contrast agents are based on benign magnetic nanoparticles (MNPs) and are starting to be used in clinical trials for MRI. Such MNPs have iron oxide cores that are superparamagnetic and so enable tracking of theranostic nanomedicines by MRI. Stoddart et al. created a targeted drug delivery system for the treatment of cancer and degenerative diseases. To date, examples of fully characterised dual-(multi)-mode imaging probes have been described for simultaneous PET/MRI or PET/MRI/NIRF (near infrared fluorescence). The preparation of serum albumin modified MnFe₂O₄ nanoparticles conjugated with ¹²⁴I has been reported. Amino acid modified MNPs coupled to cyclic arginine-glycine-aspartic acid (RGD) peptides for integrin α₅β₁ targeting with macrocyclic 1,4,7,10-tetraazacyclododecan-11-N₂,N₆,N₁₀,N₁₄-tetracetic acid (DOTA) chelators labelled with ⁶⁴Cu (t₁/₂ = 12.7 h) for PET were also described. A route to radio-labelling of dextran sulphate-coated superparamagnetic iron oxide nanoparticles with ⁶⁴Cu was developed where the radiochemical centres were coordinated to the chelating bifunctional ligand, S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecan-1,4,7,10-tetracetic acid (p-SCN-Bz-DOTA), and subsequently conjugated to the surface of the MNPs. Devaraj et al. reported the synthesis and in vivo characterisation of ¹⁸F modified tri-modal MNPs consisting of a shell of cross-linked dextran, around a core of iron oxide and functionalized with the radionuclide ¹⁸F in high yields via click chemistry. Iron oxide MNPs with a compact human serum albumin coating (HSA-IONPS), dually labelled with [⁶⁴Cu]Cu-DOTA and Cy 5.5, were synthesised as a tri-modal imaging agent for PET/MRI/NIRF. The synthesis of a probe consisting of a superparamagnetic iron oxide (SPIO) core coated with PEGylated phospholipids and hydrophobic ¹⁸F has been reported. PEG ends were conjugated to DOTA to allow labelling with ⁶⁴Cu. PEG chains were also used together with bisphosphonate anchors to SPIO NPs with [⁹⁹mTc] complexes, resulting in a multimodal in vivo imaging agent. Bisphosphonate ligands were also designed to bridge ⁶⁴Cu and SPIO NPs. Green and Blower reported the synthesis, characterisation of a series of Co₂Fe₃O₆@NaYF₄ core-shell NPs doped with ¹⁸F, offering PET/SPECT, MR and up-conversion fluorescence imaging. However, in most of these cases, complex chemical reactions are needed to radiolabel the MNPs or to anchor the fluorescent dyes. A potential problem is a possible solvolysis and/or MNP degradation that may occur over time in aqueous media and, to a higher extent, in a biological environment. In order to extend the use of the new functional MNPs to the radiopharmaceuticals, these synthetic challenges at their assembly need to be urgently addressed. Encapsulation of a molecular imaging probe for functional imaging and/or therapeutic applications within a magnetic nanoparticle represents an excellent method for kinetic stabilisation and successful delivery of the probe to the targeted tissue. Coating MNPs with silica is a promising approach since it is readily derivatised and it also reduces non-target cytotoxicity. Further, the use of quantum dots (QDs) in live-cell imaging studies has been shown to be valuable due to both their capacity as luminescent agents capable of absorption across broad wavelengths but sharp emission bands and their superior resistance to photo-bleaching compared with most commercial dyes. However, it has been reported that, although core-shell QDs can be more robust than those with organic coatings, the thickness of the inorganic shell (ZnS) can degrade the optical properties of the core. Their usefulness as imaging agents has also been hampered by controversies related to the potential toxicity of the shell materials. There is a need for fully encapsulation techniques using benign materials with retention of efficient emission in biological media and provision of highly kinetically stable species. Silica is an attractive alternative in this regard since, as noted above, it is biocompatible and can be easily functionalized.

This work aims to overcome the limitations of current systems to develop a novel series of MNPs for imaging purposes (Figure 1). Reproducible synthesis and characterisation protocols of such MNPs incorporating imaging agents such as QDs (CdSe, ZnSe and CdSe/ZnS) or ZnII/(ATSM)/A,[³⁹⁹mTc]Ga[ATSM]/A (ATSM/A = diacetyl-2-(4-N-methyl-3-thiosemicarbazonato)-3-(4-N-amin-3-thiosemicarbazonato)-3 and [³⁹⁹mTc]Ga[ATSM]/A) are reported. The radioactive tracers [³⁹⁹mTc]Cu[OAc]₂ and [³⁹⁹mTc]Cu[ATSM]/A display appreciable hypoxia selectivity versus normoxia, and can be used for the delineation of tumour cells deprived of oxygen as well as ischemic and hypoxic myocardium. The metal complex was first used in clinical trials in 2000 as an imaging agent for tumor hypoxia. Ga[ATSM]/A is a new system that so far has not shown sufficient kinetic stability in the radiolabelled form. We and others have also designed and developed new methods to incorporate radioisotopes to chelator-free nanoparticles, and characterised emerging nanomedicines in vitro and in vivo. New core-shell nanomaterials with high kinetic stability in aqueous media are reported hereby.

New nanoceramics based on hybrid systems denoted NPs and MNPs were generated via self-assembled techniques, using a novel microemulsion method while encapsulating a range of imaging agents, including: nano-materials-based species (QDs), model inorganic systems for SPECT tracers such as ⁹⁹ᵐTc-pertechnetate and/or radiotherapy (Re(VII) oxo-anionic species, ReO₄⁻, see ES1), radioactive ions for PET (¹⁸F) and corresponding radiotracer metal complexes and precursors (¹⁸F[¹⁸F]Cu[ATSM] and also their Ga(III) analogues). Fluorophores were encapsulated within a silica shell to investigate the in vitro uptake in prostate cancer cells (PC-3), a non-cancerous fibroblast cell line (FEK-4) and Chinese hamster ovary (CHO). Multiphoton fluorescence spectroscopy and imaging techniques were used for the first time to describe the environmental changes in the nature of the fluorophore upon encapsulation in NPs/MNPs and upon internalisation in cells. The potential for simultaneous and versatile derivatisation of NPs and MNPs whilst retaining their kinetic stability in the aqueous and biological environment are probed extensively by a range of...
Results and Discussion

Incorporation of Optical Imaging Agents into Core-shell Fe₃O₄@SiO₂ Magnetic Nanoparticles (MNPs)

Optimising the efficacy of a (dark) contrast MRI agent has been one of the challenges that attracted the attention of many research groups. Over the course of the years, nanotechnology offered solutions to generate contrast agents able to yield high R₂/R₁ or R₂*/R₁ ratios. Very efficient routes to enhance R₂/R₂* values are provided by the synthesis and use of SPIO NPs. To address such challenges, novel magnetic iron oxide nanoparticles were synthesised via a co-precipitation method and encapsulated with silica via a microemulsion coating method. Similar techniques have been used to synthesise uniformly sized and high quality, silica coated MNPs using a water-in-oil (W/O) microemulsion method. The formation of magnetic, crystalline Fe₃O₄ nanoparticles was confirmed by powder X-ray diffraction (ICDD file no. 86-2368, see ESI). The presence of silica was confirmed by FTIR vibrations at around 1100 cm⁻¹ (Si–O symmetric stretch) and 820 cm⁻¹ (asymmetric Si–O stretch). Magnetisation curves obtained by SQUID (Superconducting Quantum Interference Device) showed the typical characteristics of superparamagnetic behavior, zero coercivity and no remanence on hysteresis, for the NPs samples. The magnetisation (normalised per gram of sample) observed for Fe₃O₄@SiO₂ (A) was one-third of that measured for pure Fe₃O₄ MNPs. The core-shell structure of the MNPs was confirmed by TEM (Figure 2). These MNPs have consistent, almost spherical morphology and the particles are well dispersed with sizes in the range of 5–10 nm for the iron oxide cores and 50–60 nm when encapsulated by silica.

Adapting the methods established by Wu et al. and Jacinto et al., the fluorophores were incorporated hereby using a rapid and simple one-step microemulsion method. TEM micrographs of such NPs are illustrated in Fig. S9-S13 (ESI). However, none of the nanoparticles prepared using organic fluorophores exhibited significant luminescence. A reverse microemulsion method was employed to encapsulate Lumidot...
480 QDs, resulting in core-shell fluorescent Fe_3O_4/CdSe/ZnS@SiO_2 (B) composite nanoparticles, the morphology of which can be seen by TEM (Figure S14). It is well known that QDs have higher extinction coefficients and quantum yields compared with organic dyes.\cite{41,59,60}

Two-photon laser scanning confocal microscopy was performed on Fe_3O_4/CdSe/ZnS@SiO_2 (B) NPs in order to establish their potential as fluorescent imaging agents for in vitro cells and tissue studies. Chinese hamster ovary (CHO) cells were grown according to standard protocols, placed onto glass bottom dishes and allowed to grow to suitable confluence (see SI for cell culture and plating details). Figure 3a–d shows bright field confocal images, the overlay of green-red channels and individual channel emissions (green: λ_em = 515–530 nm; red: λ_em = 605–675 nm). The images prove that, over a period of 15 minutes, the nanocomposite particles are taken up into cells and distributed across the cytoplasm with a large majority of emission lying in the green and red wavelength ranges. The fluorescence lifetime map distribution in CHO cells and the associated distribution profile of a water suspension of Fe_3O_4/CdSe/ZnS@SiO_2 (B) are shown in Figure 3e–f and Figure 3g respectively. Fluorescence decays were fitted to two components. The major component (t_1, a_1 = 88.2%) had a lifetime of 230 ps. A minor and longer second component (t_2 = 3216.5 ps, a_2 = 11.8%) was also detected. As previously reported, the presence of a second longer component may suggest the presence of NP aggregates in suspension.\cite{61} However, the percentage of such secondary component, although significant, remains lower (11.8%) than that previously reported for nanocomposite materials (31.1%).\cite{61} These studies suggest, therefore, that simultaneous encapsulation of QDs and magnetic Fe_3O_4 nanocrystals into a SiO_2 shell produces a nanocomposite material capable of being internalized and producing a stable
Encapsulation of Cadmium Quantum Dots into MNPs

Cadmium-containing quantum dots are known to be toxic, which is in large part attributed to the presence of free Cd²⁺ ions released when non-coated QDs are exposed to the acidic microenvironment after cellular uptake.[61,62] Soenen and collaborators[63] employed the degradation of cadmium quantum dots to correlate the loss of fluorescence intensity the number of cancer cells. Recent studies have shown that the toxicity of NPs can also be exploited as a novel means of providing cancer therapeutic effects. Pompa et al.[64] reported that ion-releasing NPs may induce high levels of cytotoxicity due to the so-called lysosome-enhanced Trojan horse effect. Furthermore, recent studies have demonstrated that the surface coating of QDs can substantially influence the toxicity of the particles.[65] Particularly, Chu and collaborators demonstrated that the silica coating of CdSe QDs reduces the release of Cd ions by up to 99.45%.[66]

We also report the synthesis of a less-common species of quantum dots, Cd₀.₁Zn₀.₉Se. Cd₀.₁Zn₀.₉Se nanocrystals were synthesised as reported by Knoll et al.[67] by doping CdSe with Zn(II) cations and Se(0) stabilised in solution via organic phosphines.[68,69] Unlike the commercially available CdSe/ZnS QDs used above, in this QD system the Zn(II) and Se are not part of the protective shell of CdSe but are effective elements of the quantum dot core, capable of emitting simultaneously in the blue and red regions of the spectrum. Encapsulation of Fe₂O₃ and quantum dots with a silica shell to form Fe₂O₃/Cd₀.₁Zn₀.₉Se@SiO₂ (C) proceeded via a microemulsion method. While Ying et al. reported the synthesis of the first QD doped MNPs encapsulated within silica,[70,71] their method required 48 h for completion.

Our method (see ESI) produces effective nanomaterials suitable for optical biosensing in a considerably shorter period of time (16 h or less) which is fully adaptable to work under the confinements of a radiochemical laboratory.

Figure 2d shows a typical TEM micrograph of core-shell Fe₂O₃/Cd₀.₁Zn₀.₉Se@SiO₂ (C) NPs, indicating dimensions around 50–60 nm. Dynamic light scattering (DLS) showed that dispersions in chloroform Cd₀.₁Zn₀.₉Se and of Fe₂O₃, Fe₂O₃/Cd₀.₁Zn₀.₉Se@SiO₂ (C) NPs in water had size distributions centered at 25, 45 and 300 nm respectively (Figure S23, ESI). Although the DLS suggests a small amount of aggregation in solution, it is known that this technique yields higher diameters than those observed by TEM.[72,73] TEM and HRTEM demonstrate that the NPs have a core-shell structure with a dark contrast metal core and a light contrast silica shell. The successful incorporation of Fe₂O₃ and Cd₀.₁Zn₀.₉Se into silica shell NPs was confirmed by optical spectroscopy and the presence of Fe, Zn, Cd and Se peaks (Figure S17–S20) in energy-dispersive X-ray (EDX) spectra. The atomic percentage of Fe and Se were 5.98% and 1.01%, respectively, which approximately corresponds to a 2:1 Fe₂O₃/Cd₀.₁Zn₀.₉Se ratio. The FTIR spectrum and magnetization curves are shown in Figure S22 (ESI).

Both the freshly synthesised Cd₀.₁Zn₀.₉Se and the corresponding nanocomposites Fe₂O₃/Cd₀.₁Zn₀.₉Se@SiO₂ (C) exhibit fluorescence emission assignable to these QDs. Figure 4 shows the fluorescence spectrum of Cd₀.₁Zn₀.₉Se QDs recorded in dilute hexane dispersions (λex = 350 nm and λem = 252 nm) and Fe₂O₃/Cd₀.₁Zn₀.₉Se@SiO₂ (C) in methanol dispersions. Free, non-encapsulated QDs emit between 360–460 nm and 535–670 nm with λmax at 395 nm and 607 nm, respectively. The relative fluorescence quantum yield (QY) for Cd₀.₁Zn₀.₉Se was determined before and after silica encapsulation and estimated with respect to anthracene in cyclohexane as a standard.[74,75] The quantum yield of freshly prepared Cd₀.₁Zn₀.₉Se was 0.15 (λmax at 350 nm) and 0.14 (λmax = 252 nm). It is interesting to note that Fe₂O₃ and SiO₂ present simultaneously act as passivating agents for the Cd₀.₁Zn₀.₉Se nanocrystals.[76,77] The fluorescence spectrum (λmax = 252 nm) of silica-encapsulated Fe₂O₃/QDs shows the characteristic emission peaks in the red (552–687 nm) and blue (277–368 nm) regions with λmax at 301 nm and 593 nm, respectively. UV-Visible spectra of the QDs before and after silica encapsulation are shown in Figure S24 and S25 (ESI) respectively. The presence of Fe₂O₃ and the silica shell around Cd₀.₁Zn₀.₉Se decreased the QY. Indeed, for Fe₂O₃/Cd₀.₁Zn₀.₉Se@SiO₂ (C) NPs the fluorescence was reduced by a factor of 100 (QY = 0.0014). Despite showing a significantly reduced fluorescence QY, the Fe₂O₃/Cd₀.₁Zn₀.₉Se@SiO₂ (C) NPs retained a luminescence emission profile which was traceable in dried thin films by confocal fluorescence microscopy.

Epi-fluorescence microscopy (Figure S50a–e) was used for PC-3 cells incubated with a DMSO:RPMI serum free medium (1:99) suspension (10 μg/mL) of Fe₂O₃/Cd₀.₁Zn₀.₉Se@SiO₂ (C) in
order to establish the potential of such NPs as cancer cell imaging agents. PC-3 cells were grown according to standard serial passage protocols, plated onto glass bottom dishes and allowed to grow up to a suitable confluence (see SI for cell culture and plating details). The Fe$_3$O$_4$/Cd$_{0.1}$Zn$_{0.9}$Se@SiO$_2$ (C) NPs are up taken in PC-3 cells, with higher emission in the blue and green wavelengths and lower emission in the red wavelengths. Figure 5 shows confocal microscopy imaging of PC-3 cells incubated for 15 minutes with Fe$_3$O$_4$/Cd$_{0.1}$Zn$_{0.9}$Se@SiO$_2$ (C) NPs. Final concentration: 10 $\mu$g/mL in 1:99 DMSO:serum free medium at 37°C. a) DIC channel; b) blue channel ($\lambda_{em} = 417$–477 nm); c) green channel ($\lambda_{em} = 500$–550 nm); d) red channel ($\lambda_{em} = 570$–750 nm); e) overlapping of the DIC, blue, green and red channels. $\lambda_{ex} = 405.0$ nm. Scale bar: a–e) 20 $\mu$m.

Figure 5. a–e) Single-photon laser-scanning confocal microscopy of PC-3 cells incubated for 15 minutes with Fe$_3$O$_4$/Cd$_{0.1}$Zn$_{0.9}$Se@SiO$_2$ (C) NPs. Final concentration: 10 $\mu$g/mL in 1:99 DMSO:serum free medium at 37°C.

Conclude that while the Fe$_3$O$_4$/Cd$_{0.1}$Zn$_{0.9}$Se@SiO$_2$ (C) NPs are effectively internalised within the cell, they do not penetrate the nuclear membrane.

Cellular uptake of these nanocomposite particles was also conducted using a non-cancerous fibroblast cell line, FEK-4, (Figure S34–S38, ESI). No alteration in the morphology of the cells was apparent up to 6 hours after addition, a timescale far exceeding most common cellular imaging experiments in living cells. After 4 h incubation, a z-stacking experiment showed that the NPs are evenly distributed throughout the cytoplasm in addition to adhering to the outer cellular membrane. It is frequently assumed that adherence to the cell surface may be the beginning of uptake via endocytosis; in our hands, however, internalisation was not observed within a standard time-point imaging experiment (e.g. 1 h incubation at either 37°C or 4°C).

The biocompatibility of mesoporous silica NPs has been extensively studied in the past and as such it is known that the toxicity of silica NPs is a concentration-dependent factor. While silica NPs are deemed biocompatible towards HeLa and CHO cells at concentrations below 100 $\mu$g mL$^{-1}$, concentrations above 200 $\mu$g mL$^{-1}$ are believed to cause cellular damage. Our experiments are carried out by using final concentrations (10 $\mu$g/mL) that are 200 times lower that one resulting in cellular degradation. Furthermore, over the course of four hours, the morphology of FEK-4 is largely unchanged. Such results and considerations seem to suggest that the concentration of the silica NPs used during our experiments are unlikely to produce cellular damage. Therefore, the internalization should not be considered as a result of cellular degradation.

The observation that these nanoparticles are fully dispersible and kinetically stable in aqueous media, yet do not appear to penetrate the cellular membrane over short timescale in such a typical (healthy) cell line is promising for their use in future bioimaging applications of gallium-68. They are potentially valuable as imaging probes where it is desirable that nanoimaging agents do not enter healthy (non-diseased) cells in an uncontrolled manner. They are stable over lifetimes compatible with the short half-lives of gallium-68 and with optical imaging experiments.

By encapsulating the Cd$_{1}$Zn$_{8}$Se nanocrystals in a thin silica matrix along with magnetic nanoparticles, we achieved a water dispersible system that retains the optical features of the free QDs as well as the magnetic properties of the iron oxide core. To the best of our knowledge, such NPs represent the first example of coated QDs which emit in two different and distinct regions of the spectrum. These fluorescent features potentially make such inorganic NPs a unique and versatile device for biological applications. Therefore, we explored the possibility that this may render these core-shell materials as a tool for in vitro fluorescence imaging or ratiometric uses in environmental sensing.
Functionalisation of the MNPs Surface with a Known Hypoxia Tracer

The presence of a silica layer provides an opportunity for further functionalization being easily decorated with ligands such as biomolecules or drugs. Lu et al. reported that the monoclonal antibody to the β unit of human chorionic gonadotropin (anti-β-hCG) is adsorbed on the silica surface, adopting a “flat-on” conformation at the interface. Moreover, silica is biocompatible and protects the iron oxide from degradation or aggregation, while eliminating the toxicity of the core, as proven by our MTT assays (Figure 6).

To illustrate one possibility for exploiting this potential functionalization, we incorporated into the design metal-ligand complexes that have potential selectivity for hypoxic tissue in vivo and in vitro and which were studied extensively in its radiocopper bis(thiosemicarbazonato) forms. Functionalization methodologies of zinc bis(thiosemicarbazonato) complex precursors were reported: Dilworth et al. investigated the reaction of amino-tagged bis(thiosemicarbazonato) complexes of the ligand denoted [ATSM]/A with α-β-D-glucose as proof of principle of bioconjugation processes. To demonstrate that the outer surface of our \( \text{Fe}_3\text{O}_4\@\text{SiO}_2 \) \( \text{A} \) NPs can be functionalized via a condensation reaction, we investigated the reaction between \( \text{Fe}_3\text{O}_4\@\text{ATSM} \) \( \text{A} \) and \( \text{ATSM} \)/A metal complexes with a pendant amino group. For example, the amino group of \( \text{Zn}[\text{ATSM}]/\text{A} \) can react to form Si–N bonds at the surface. \( \text{Fe}_3\text{O}_4\@\text{ATSM} \) \( \text{A} \) NPs and \( \text{Zn}[\text{ATSM}]/\text{A} \) were heated under reflux overnight in methanol. Single-photon confocal microscopy images of PC-3 cells incubated with \( \text{Fe}_3\text{O}_4\@\text{ATSM} \) \( \text{A} \) \( \text{D} \) NPs are shown in Figure S51–S52. The presence of a silica layer provides an opportunity for further functionalization, we incorporated into the design metal-ligand complexes that have potential selectivity for hypoxic tissue in vivo and in vitro allows the magnetic and fluorescent nanocomposites with both \( 68\text{Ga} \) and \( 64\text{Cu} \) radioisotopes to be used to devise radiolabelling protocols but this remains a synthetic challenge since the processes involved are under subtle kinetic control.

In this work, we demonstrate that it is possible to radiolabel the magnetic and fluorescent nanocomposites with both \( 68\text{Ga} \) and \( 64\text{Cu} \) radioisotopes via the general methods developed, in most cases via chelator-free methods. \( 68\text{Ga} \) and \( 64\text{Cu} \) offer different advantages. They both undergo \( \beta^- \) decay, which allows in vivo PET imaging. \( 64\text{Cu} \) also has a characteristic low energy \( \beta^- \) emission which is effective for radiotherapy of tumour lesions with minimal effect on surrounding tissues. Regarding their production, \( 64\text{Cu} \) is available through a cyclotron, whilst \( 68\text{Ga} \) can be obtained from a commercial generator.

To address radioactivity incorporation challenges, four radiolabelling methods were devised as summarised in Figure 7. Method 1 involves non-covalent adsorption of \( [64\text{Ga}] \) GaCl\(_3\) onto the silica surface of \( \text{Fe}_3\text{O}_4\@\text{SiO}_2 \) (A) and \( \text{Fe}_3\text{O}_4/Cd\text{ZnSe} \) (C) (A) and \( \text{C} \) NPs were dispersed in DMSO and heated to 95 °C for 40 min with the pH adjusted to 4.5. For all radiolabelling experiments, a sodium acetate buffer was used as an adjuvant to improve the encapsulation yield and to adjust the pH. The resulting magnetic nanomaterials were separated using a permanent magnet and centrifuged. The particles were then washed with methanol and water.

The formation of a second silica shell around these nanocomposites which trapped the radionuclides was explored using method 2 with \( [68\text{Ga}] \) GaCl\(_3\) and \( [64\text{Cu}] \) Cu(OAc)\(_2\). By

Such aggregates might be caused by a dynamic interaction between the particles and endosomes/lysosomes, as recently reported by Gu and collaborators.

Cellular Viability Tests

Standard MTT assays were performed in order to investigate the effect of silica encapsulation and surface functionalization on the cellular viability compared with pristine QDs (Figure 6). \( \text{Fe}_3\text{O}_4/Cd\text{ZnSe} \) \( \text{SiO}_2 \) \( \text{C} \) NPs have similar IC\(_{50}\) to cisplatin which is used to treat a variety of tumours (IC\(_{50}\) = 7.20 · 10\(^{-8}\) mg/mL measured over 72 h). The IC\(_{50}\) had lower (up to ten times) cytotoxicity (IC\(_{50}\) = 6.76 · 10\(^{-4}\) mg/mL) than the Cd\(_{0.1}\)Zn\(_{0.9}\)Se (IC\(_{50}\) = 5.07 · 10\(^{-5}\) mg/mL) nanocrystals (Figure 6). The functionalization of the silica shell lowers IC\(_{50}\) (6.77 · 10\(^{-3}\) mg/mL) from that of the unmodified surface. This might be caused by loss of metal cations. However, the results demonstrate that encapsulation of Cd\(_{0.1}\)Zn\(_{0.9}\)Se and Fe\(_3\)O\(_4\) NPs within a silica shell improves the in vitro biocompatibility of the QDs used in this work.

Radiolabelling of Nanocomposites using PET Isotopes \( \text{Cu} \) and \( \text{Ga} \)

The ability to functionalise the surface of the nanocomposite particles offers the possibility of supramolecular trapping or encapsulation of a radionuclide under the limited or no-carrier-added radiochemistry conditions. Various approaches have been used to devise radiolabelling protocols but this remains a synthetic challenge since the processes involved are under subtle kinetic control.

In this work, we demonstrate that it is possible to radiolabel the magnetic and fluorescent nanocomposites with both \( 68\text{Ga} \) and \( 64\text{Cu} \) radioisotopes via the general methods developed, in most cases via chelator-free methods. \( 68\text{Ga} \) and \( 64\text{Cu} \) offer different advantages. They both undergo \( \beta^- \) decay, which allows in vivo PET imaging. \( 64\text{Cu} \) also has a characteristic low energy \( \beta^- \) emission which is effective for radiotherapy of tumour lesions with minimal effect on surrounding tissues. Regarding their production, \( 64\text{Cu} \) is available through a cyclotron, whilst \( 68\text{Ga} \) can be obtained from a commercial generator.

To address radioactivity incorporation challenges, four radiolabelling methods were devised as summarised in Figure 7. Method 1 involves non-covalent adsorption of \( [64\text{Ga}] \) GaCl\(_3\) onto the silica surface of \( \text{Fe}_3\text{O}_4\@\text{SiO}_2 \) (A) and \( \text{Fe}_3\text{O}_4/Cd\text{ZnSe} \) (C) (A) and \( \text{C} \) NPs were dispersed in DMSO and heated to 95 °C for 40 min with the pH adjusted to 4.5. For all radiolabelling experiments, a sodium acetate buffer was used as an adjuvant to improve the encapsulation yield and to adjust the pH. The resulting magnetic nanomaterials were separated using a permanent magnet and centrifuged. The particles were then washed with methanol and water.

The formation of a second silica shell around these nanocomposites which trapped the radionuclides was explored using method 2 with \( [68\text{Ga}] \) GaCl\(_3\) and \( [64\text{Cu}] \) Cu(OAc)\(_2\). By

Such aggregates might be caused by a dynamic interaction between the particles and endosomes/lysosomes, as recently reported by Gu and collaborators.\(^{[62]}\)
following method 2, $^{68}$GaCl$_3$ was added to a DMSO suspension of Fe$_3$O$_4$@SiO$_2$ (A) or Fe$_3$O$_4$/Cd$_{0.1}$Zn$_{0.9}$Se@SiO$_2$ (C) NPs with TEOS and cyclohexane. The resulting mixture was heated to 95°C for 68 min. The added TEOS generated a second layer of silica trapping the radioisotope. The resulting radiochemical incorporation was found to be 70%, and due to the short half-life of $^{68}$Ga, the reaction conditions could not be further optimised. However, the longer half-life of $^{64}$Cu allowed us to validate the radiolabelling protocol in water at room temperature (see ESI). $^{64}$Cu(OAc)$_2$ was incorporated as the radioactive material following methods 2 and 3. In order to optimise the radiolabelling protocols, six different parallel assembly routes were used (details are given in ESI). Different amounts of $^{64}$Cu radiotracer were added during the coating process at pH 8.

The longer half-life of $^{64}$Cu(OAc)$_2$ allowed for a 7 h, one-pot encapsulation protocol (method 3) using Fe$_3$O$_4$, $^{64}$Cu(OAc)$_2$, and TEOS. These three methods give a general approach which is also valid for other metal isotopes in aqueous media. The methods can be adjusted to suit the half-life of the particular radionuclide, such as $^{89}$Zr ($t_{1/2} = 78.4$ h). While methods 1, 2 and 3 are based on the self-assembly of the precursors within a silica network, we also investigated in method 4 (details in ESI) the possibility of radiolabelling Fe$_3$O$_4$@SiO$_2$@Zn[ATSM]/A (D) NPs via a transmetalation reaction involving Zn and the relevant radionuclide (e.g. $^{68}$Ga ions) in aqueous media.

Taking into account the half-life of both radioisotopes, the decay-corrected radiolabel incorporations were estimated. Over 99.9% incorporation was achieved from the non-covalent adsorption of aqueous $^{68}$GaCl$_3$ onto the silica surface. A value of 94% was achieved using $^{64}$Cu(OAc)$_2$ in a one-pot protocol (method 3), and 84% was obtained by following a step-wise reaction with the same radioisotope (method 2). Using $^{68}$GaCl$_3$ in method 2 led to 70% incorporation of the radionuclide. The method using transmetalation of
facilitates the radiochemical incorporation of $^{68}$GaCl₃ as in $^{64}$Cu(OAc)$_2$ although with $^{68}$Ga the radiochemical incorporation increased to $> 99.9\%$. However, this remarkable value may well be explained by a surface adsorption process which facilitates the radiochemical incorporation of $^{68}$GaCl₃ as in method 1. The maximum efficiency was reached when $^{68}$Ga was injected into a suspension of silica coated NPs, following method 1. As a control, free Zn[ATSM]/A in ethanol was subjected to the same experimental conditions used for radiolabelling Fe$_3$O$_4$@SiO$_2$@Zn[ATSM]/A (D) NPs. According to previous work by Pascu and co-workers,$^{49}$ the labelling of Zn[ATSM] complexes with $^{68}$Ga was unsuccessful. Therefore, we conclude that the covalent bond between the ATSM ligand and the silica surface plays a crucial role in the $^{68}$Ga radiolabelling process.

Virtually no loss of the radioactivity of the $^{64}$Cu radiolabelled nanoparticles dispersed in water was noted 7 h after encapsulation, showing that the encapsulated material does not leak out. The loading mechanism of $^{64}$Cu acetate (a well-known monohydrate complex which adopts the paddle-wheel structure$^{30}$ of ca. 9 Å diameter) is likely based on solvophobic interactions reinforced by H-bonds within the [SiO$_4$]₄ matrix formed in the microemulsion environment, efficiently trapping the radionuclide and resulting in leak-free radioactive nanoparticles which are stable in aqueous media for weeks. After decay (3 weeks), TEM micrographs of the $^{64}$Cu radiolabelled MNPs were compared with freshly prepared, non-radioactive nanoparticles. When $^{64}$Cu solution was added after the pre-coating period (method 2), the shape of the core-shell NPs was maintained (ESI) and no significant changes in shape and size or in aggregation were observed. These results demonstrate the possibility of synthesising a trimodal imaging agent which is highly stable with respect to radioactive agent loss. The results with the highest labelling incorporation percentage following each different radiolabelling method are reported in Table 1 and Figure 8.

Conclusions

In conclusion, magnetic iron oxide nanoparticles incorporating Fe$_3$O$_4$ cores and Cd$_{0.1}$Zn$_{0.9}$Se quantum dots were simultaneously encapsulated within ca. 10 nm silica shell, giving rise to water-dispersible, biocompatible and luminescent NPs with dimensions, ranging between 30–50 nm, which retained the magnetic properties. These were found to retain some of the emissive characteristics of the encapsulated QDs while still exhibiting magnetic properties due to the Fe$_3$O$_4$ core. Cellular interactions over a timescale of 30 min–6 h and incubation at 37°C were visualised by epi- and confocal fluorescence microscopies. Surface modification allowed incorporation of two radiolabelled, Gallium-68 and Copper-64. The materials appear to be non-toxic and constitute a promising, safe-to-handle and benign hybrid nanoparticles of potential utility as tri-modal medical imaging probes that allow a simultaneous PET, MRI and fluorescence imaging. However, the optimization of the formulation for an effective and simultaneous use of these nanocomposites for multimodal imaging remains a challenge. While this study has focused mainly on new fine-tuning encapsulation methods, preliminary experiments suggest that this approach can be extended to biologically or medically relevant nanoscaffolds and offers the potential for measuring the speciation of such systems in living cells. In future we

---

**Table 1. Summary of optimised radiolabelling methods and associated radio-incorporation (%) with respect to precursors.**

| Procedure | Compound | Radiosotope | %  |
|-----------|----------|-------------|----|
| Method 1  | (G); (E) | $^{68}$GaCl₃ | $>99.9 \pm 0.1$ |
| Method 2  | (L)      | $^{64}$Cu(Cu(OAc)$_2$ | $84 \pm 0.5$ |
| Method 3  | (J)      | $^{68}$GaCl₃ | $70 \pm 0.5$ |
| Method 4  | (F)      | $^{64}$Cu(Cu(OAc)$_2$ | $94 \pm 0.5$ |
| Method 5  | (H)      | $^{64}$Cu(Cu(OAc)$_2$ | $65 \pm 0.5$ |
| Method 6  | (I)      | $^{68}$GaCl₃ | $>99.9 \pm 0.1$ |
envisage to extend this work towards other relevant PET radionuclides such as fluorine-18.  

Experimental Section

All manipulations were carried out by using standard Schlenk glassware and glove box techniques. All solvents were used as purchased and degassed by bubbling nitrogen for 30 min. Trioctylphosphine oxide (TOPO, 99%), trioctylphosphine (TOP, 90%), octadecylamine (ODA, 90%), stearic acid (95%), diethylzinc (ZnEt2, 1.0 M solution in heptane), and Se powder (99.999%) were purchased from Aldrich. Cadmium stearate was purchased from Greyhound Chromatography. Zn(ATSM)/A was synthesised in accordance with a previously reported procedure. Further details of the experimental synthetic procedures used to synthesise compounds and materials mentioned in this work can be found in the supporting information. TEM micrographs, IR spectra, DLS, UV-vis, 2D fluorescence spectra, as well as information regarding cell culture, MTT assays, epifluorescence and confocal microscopy imaging are also given in the SI.

Synthesis of Fe3O4 Nanoparticles

10 mL of 1 M FeCl3 were mixed with 2.5 mL of 2 M FeCl3 dissolved in 2 M HCl. Both solutions were freshly prepared with deoxygenated water before use. Immediately after being mixed under nitrogen, the solution containing iron chlorides was added to 125 mL of potassium hydroxide solution (0.7 M) under vigorous mechanical stirring and under a nitrogen atmosphere. After 30 min, the black precipitate formed was separated magnetically using a standard permanent magnet and washed with water (3×25 mL). Finally, oleic acid (5 mmol) was dissolved in 5 mL of acetone and was dropwise added.

Coating of MNPs with a Silica Shell using Microemulsion Method

44.60 g of polyoxyethylene(5)isooctylphenyl ether (IGEPAL CA-520) was dispersed in 700 mL of cyclohexane. Then, 200 mg of Fe3O4 nanoparticles dispersed in cyclohexane (20 mg/mL) 1 was added. The mixture was stirred until it became transparent. After this step, 9.44 mL of ammonium hydroxide (29% aqueous solution) was added to form a reverse microemulsion. Finally, 7.70 mL of tetraethyloxysilicate (TEOS) was added. The solution was gently stirred for 16 h. The nanocomposite was precipitated with methanol and separated by magnetic decantation.

Synthesis of Cd1−xZnxSe QDs

Stock solutions for Se and ZnEt2 were prepared in a glovebox under argon atmosphere. Cadmium stearate (0.2044 g, 0.3 mmol), stearic acid (0.1707 g, 0.6 mmol), TOPO (5.0 g), and ODA (5.0 g) were added to a flask, and the mixture was heated, under stirring, to 330 °C under a flow of argon until a clear solution formed. At this temperature, a solution containing 0.1184 g of Se (1.5 mmol) dissolved in TOP was injected into the reaction flask and the temperature was set to 290 °C. After 5–10 min, under stirring, the heating was removed to stop the reaction and allow the flask to cool to room temperature. After 1 h, the mixture of CdSe and organic ligands was heated up to 300 °C again. An aliquot (5 mL) of the as-prepared crude CdSe reaction mixture, containing 0.1 mmol of CdSe, were transferred to a three-neck Schlenk flask and heated at 300 °C. At this temperature, 0.450 mL of ZnEt2 (TOP solution, 0.2 M) and 0.450 mL of Se (TOP solution, 0.2 M) were injected. The reaction mixture was heated for 6 min. Once the mixture reached room temperature, 9 mL of chloroform was added under stirring. Quantum dots were precipitated in a mixture 1:1 of methanol/acetone and isolated by centrifugation and decantation. A mixture of methanol/acetone (5×25 mL) was used to wash the QDs from the excess of organic ligands. Finally, Cd1−xZnxSe nanocrystals were dispersed in 9 mL of n-hexane and characterized by optical spectroscopy.

Synthesis of Fe3O4/Cd1−xZnxSe@SiO2 (C) NPs

In a typical experiment, 0.223 g of polyoxyethylene(5)isooctylphenyl ether was dispersed in 3.5 mL of cyclohexane. Then, 1.0 mg of Fe3O4 dispersed in cyclohexane (20 mg/mL) was added, followed by 30 μL of QD (1.50 mg/mL). The mixture was stirred until it became transparent. After this step, 45 μL of ammonium hydroxide (29% aqueous solution) was added to form a reverse microemulsion. Finally, 39 μL of TEOS was added. The solution was gently stirred for 16 hours. The nanocomposite was precipitated with methanol and separated by magnetic decantation.

Synthesis of 68Ga Radiolabelled MNPs

[68Ga]GaCl3 was produced and eluted through a 68Ge/68Ga generator in a saline/HCl (0.02 M) solution. Method 1. 50 μL of MNPs (A and C) (1 mg/mL DMSO stock solution) was dispersed in 0.4 mL of ethanol. 100 μL of [68Ga]GaCl3 stock solution (37 MBq in 500 μL) was added to the suspension, and the pH was adjusted to 5 by adding 1 mL of sodium acetate buffer solution (pH 4.5). The reaction was carried out for 40 min at 90 °C (using the vortex every 10 minutes). Method 2. 0.223 g of polyoxyethylene (5) isooctylphenyl ether (IGEPAL CA-520) was dispersed in 3.5 mL of cyclohexane. Then, 30 μL of MNPs (A and C) (dispersed in DMSO (1 mg/mL)) was added and the mixture was stirred in a vortex. Next, 45 μL of ammonium hydroxide (29% aqueous solution) was added to form a reverse microemulsion, followed by 15 μL of TEOS. Finally, 50 μL of [68Ga]GaCl3 stock solution was added to the reaction vial, the solution was heated to 90 °C and reacted for 68 min (sonicated every 10 min). Method 4. 50 μL of Fe3O4/SiO2@Zn(ATSM)/A (D) NPs (2 mg/mL DMSO stock solution) was dispersed in 0.4 mL of ethanol. 100 μL of [68Ga]GaCl3 stock solution (37 MBq in 500 μL) was added to the suspension, and the pH was adjusted to 5 by adding 1 mL of sodium acetate buffer solution (pH 4.5). The reaction was carried out for 40 minutes at 90 °C (using the vortex every 10 minutes). For all the experiments, the nanocomposite was transferred to centrifuging vials and washed with 0.5 mL of methanol and water (3×0.5 mL) and separated by magnetic decantation or using centrifugal filters. Each experiment was carried out three times.

Synthesis of 64Cu Radiolabelled MNPs

[64Cu]CuCl2 was produced on a medical cyclotron using the 64Ni(p,n)64Cu nuclear reaction and purified using an ion-exchange column. A stock solution of [64Cu]Cu(OAc)2 was prepared at pH 8.4, using 10 mM NaOAc solutions. Method 2 and 3. 0.223 g
of polyoxylethylene (5) isooctylphenyl ether was dispersed in 3.5 mL of cyclohexane. Then, 1.0 mg of Fe₃O₄ (or A) dispersed in cyclohexane (20 mg/mL) was added. The mixture was stirred until it became transparent. After this step, 45 μL of ammonium hydroxide (29% aqueous solution) was added to form a reverse micromulsion, followed by 15 μL of TEOS. The reaction was carried out for 2 hours and subsequently, 25 μL of [⁶⁴⁰Cu(CuOAc)₂](aq) (from a 100 MBq stock solution) was added together with an additional 24 μL of TEOS. The solution was gently stirred for 5 hours. Method 4. 50 μL of D (1 mg/mL DMSO stock solution) was dispersed in 0.4 mL of H₂O. 0.2 mL of [⁶⁴⁰Cu(CuOAc)₂](aq) solution was added to the suspension. The reaction was carried out for 40 minutes at 90 °C (using the vortex every 10 min). For all the experiments, the nanocomposite was precipitated with methanol (3×0.5 mL) and separated by magnetic decantation. Each experiment was carried out three times.

Acknowledgements

The authors are grateful for the helpful contributions, discussions and training received from the following: Professors Jason Lewis, Stephen Faulkner, and Philip Blower (MSKCC New York, Oxford and London KCL, respectively) and Drs H. Betts and P. Waghorn (Oxford and Harvard, respectively). The authors would like to thank Drs Paul Burke and Patrick Riss (Wolfson Brain Imaging Centre, Addenbrooke’s Hospital, Cambridge) for provision of ⁶⁴⁰Cu and training in this facility. Dr. Adrian T. Rogers (Microscopy and Analysis Suite, Prof. Rex M. Tyrrell (Department of Pharmacy & Pharmacology at the University of Bath), Rebecca Diment (Bath), Dan Lee (Oxford), Drs Justin P. O’Byrne and Stephen E. Flower are thanked for their invaluable contribution to preliminary aspects of this work. We thank Dr Michael W. Jones (Oxford) for assistance with the acquisition of some of the fluorescence microscopy images, Professor Quentin Pankhurst (ULC) for assistance with magnetic measurements and Dr N. Rees (Oxford) for paramagnetic NMR work. Dr Petra Cameron is thanked for assistance with early-stage tests on a proof-of-principle quantum dot encapsulation. The authors thank the Royal Society, EPSRC and MRC for funding, also the EPSRC Mass Spectrometry service (Swansea). The team was also funded by the European Commission FP7 Programme through the Marie Curie Initial Training Network PROSENSE (grant no. 317420, 2012–2016) and SIP also thanks the European Commission for an ERC Consolidator Grant (O2SENSE Program 617107, 2014–2019).

Conflict of Interest

The authors declare no conflict of interest.

Keywords: core-shell nanoparticles · cellular bioimaging · hypoxia · radiochemistry · self-assembly
